1. Corporate Communications 2012 Oncology Specialty Survey November 2012

2. 2 Practice Size Survey Overview 8% Solo33% Hospital16% Small (3-5 physicians) 4% Partnership 15% Large (More than 10 physicians) 20% Mid-size (5-10 physicians) Survey included 321 Oncologists who use Epocrates Survey was conducted in October 2012 Oncologists randomly selected to participate 2 Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com n=321

3. >1 in 3 Oncologists use a Tablet in Practice > = > Other devices primary; tablet supplemental Tablet only device used Rarely uses tablet Tablet primary; other device supplemental Tablet & other devices used equally 45% 27% 15% 11% 2% 37% Plan to purchase iPad mini37% 80% Apple iPad 15% Android OS Tablet utilization in practice 2% Other 3% Windows 7 OS Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com 3 n=105 n=122 n=321

4. Oncologists Access Epocrates Over 2 Million Times Annually with a Patient* 70 % 60 % Use Epocrates Outside of the office Outside of the office daily Use Epocrates During office hours 3+ During office hours 3+ times daily Use Epocrates With a patient daily Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com 4 n=321 Number of times physicians access Epocrates Over 1 in 2 *Statement based on self-reported usage and extrapolated across the Epocrates member base

5. Nearly 40% of Oncologists Avoid 2+ ADEs Weekly with Epocrates Over450,000 ADEs are potentially avoided annually with Epocrates* Over450,000 ADEs are potentially avoided annually with Epocrates* Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com 5 Percentage of ADEs avoided with Epocrates n=321 *Statement based on self-reported usage and extrapolated across the Epocrates member base

6. Over 400,000 Hours Likely Saved by Oncologists Annually with Epocrates* Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com 6 20+ minutes saved daily n=321 *Statement based on self-reported usage and extrapolated across the Epocrates member base oncologists report saving 20 minutes or more daily Nearly 1 in 2 Daily minutes saved

7. 54% Frequently or somewhat frequently learn new information from DocAlerts54% Drug Interaction Checker #1 Feature Attributed to Changing Rx Decisions 72 % Drug interactions 71 % Dosing information 46 % Adverse reactions 43 % Contraindications & cautions 15 % Formulary information 12 % Other safety info 92% Make Rx changes based on Epocrates information92% Make Rx changes based on Epocrates information Top features factoring in Rx changes* Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com 7 n=321

8. 34% Yes, significantly 31% Yes, moderately 25% Yes, somewhat 10% No Keeping Up with New Clinical Info a Top Challenge for Oncologists Years in practice Has the level of stress grown over the years as practicing physician? Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com 8 n=321

9. 9 Fragmented Care Biggest Challenge Facing Patients Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com Top 5 greatest challenges for patients 93% Diagnosis 91% Tx Options 79% Prognosis 62% Viability estimates Extremely confident to confident Confidence in information disclosed to patients n=321

10. Rx information Lifestyle change tools Chronic Dx mgmt Medical adherence EHR portal Patient education >30% of Oncologists Have Recommended an App to Patients 66% 56% 34% 25% 23% 10% 10% Apps recommended to patients Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com 10 n=106 Calorie counter/ tracker Weight loss tracker Fitness app (e.g. myfitnesspal.com) Drug information (e.g. Epocrates) Patient educational apps Calorie counter/ tracker Weight loss tracker Fitness app (e.g. myfitnesspal.com) Drug information (e.g. Epocrates) Patient educational apps

11. Physicians Struggle with App Discovery and Recommendations for Patients Where physicians learn about apps to recommend Over 50 % Report not knowing which apps are ‘good to share’ Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com 11 n=105 n=216

12. “Phone Calls” Remain Primary Communication Platform for Patients and Peers 12 Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com Physician to Patient Physician to Colleague Phone call 84% Phone call 43% Email 9% Email 32% SMS Message 2% Patient Portal 3% Direct Mail Video Chat 2% ~ 1% EmailSMS Message Direct MailVideo Chat 7%0% EHR SystemSecure Messaging 3%6% 12% Primary methods of communication with colleagues vs. patients n=321

13. 13 Perceptions of Cancer are Increasingly Positive Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com n=321 Chronic Condition: A human health condition or disease that is persistent or otherwise long-lasting in its effects* Chronic Condition: A human health condition or disease that is persistent or otherwise long-lasting in its effects* *World Health Organization 2012

14. 14 Oncologist Data and Information Gaps Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com >55% are concerned about industry bias in journal articles & clinical trials >55% Most need information to help improve patient care* 38% Comparison of anticancer therapies 38% Comparison of anticancer therapies 19% Information on enrolling in clinical trials 19% Information on enrolling in clinical trials 17% Information on research results for existing therapies 17% Information on research results for existing therapies Oncologists highly anticipate development or technology in targeted molecular and genetic therapies n=321